Larimar Therapeutics, Inc.

NASDAQ:LRMR

Biotechnology

Healthcare
$3.23 +0.99%

+$0.04 today

Market cap
$337.45M
Beta
0.82
P/E (TTM)
-1.8
EPS (TTM)
-$1.95
52W Low $2.22High $6.42

Volume 1.41M

Average 1.73M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$113.20M

FY 2025 · Annual

Investing Cash Flow

$100.31M

FY 2025 · Annual

Financing Cash Flow

$65.09M

FY 2025 · Annual

-59.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(50.64M)(35.36M)(36.95M)(80.6M)(165.67M)
Depreciation & Amortization326K318K311K318K(1.35M)
Deferred Income Tax00000
Stock-Based Compensation5.47M6.62M7.62M8.8M7M
Change in Working Capital2.75M1.67M(2.51M)6.18M47.1M
Accounts Receivables00000
Inventory00000
Accounts Payables(974K)26K(403K)1.14M2.79M
Other Working Capital3.72M1.64M(2.11M)5.03M44.31M
Other Non-Cash Items(15K)(820K)(1.93M)(5.45M)(281K)
Operating Cash Flow(42.11M)(27.57M)(33.46M)(70.76M)(113.2M)
Capital Expenditures(333K)(100K)(164K)(515K)(91K)
Acquisitions (Net)(24.5K)90.86K000
Purchases of Investments(8.25M)(133.61M)(101.23M)(227.87M)(83.6M)
Sales of Investments32.75M42.75M134.75M143M184M
Other Investing Activities24.5K(90.86K)000
Investing Cash Flow24.17M(90.96M)33.35M(85.39M)100.31M
Debt Repayment00000
Common Stock Issued19.89M75.26M30K161.81M65.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00077K0
Financing Cash Flow19.89M75.26M30K161.88M65.09M
Effect of Forex Changes00000
Net Change in Cash1.95M(43.27M)(76K)5.74M52.19M
Free Cash Flow(42.44M)(27.67M)(33.62M)(71.28M)(113.29M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$165.7M
+ D&A-$1.3M
+ Stock-Based Comp$7.0M
+ Deferred Tax$0
+ Working Capital$47.1M
- Other Non-Cash-$281.0K
= Operating Cash Flow-$113.2M
- Capex-$91.0K
= Free Cash Flow-$113.3M

Analysis

FY2025 free cash flow is -$113.3M. FCF conversion is 68.4% of net income. Operating cash flow was -$113.2M, with capex of -$91.0K. The largest bridge item is Working Capital at $47.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026

Does LRMR generate free cash flow?

Larimar Therapeutics, Inc. (LRMR) generated -$113.29M of free cash flow in fiscal 2025.

How much operating cash flow does LRMR produce?

Operating cash flow was -$113.20M, before capital expenditures of $91,000.00.